These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 31102009)

  • 1. Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-naïve, HER2-positive advanced gastric cancer.
    Takahari D; Chin K; Ishizuka N; Takashima A; Minashi K; Kadowaki S; Nishina T; Nakajima TE; Amagai K; Machida N; Goto M; Taku K; Wakatsuki T; Shoji H; Hironaka S; Boku N; Yamaguchi K
    Gastric Cancer; 2019 Nov; 22(6):1238-1246. PubMed ID: 31102009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter phase II study of SOX plus trastuzumab for patients with HER2
    Yuki S; Shinozaki K; Kashiwada T; Kusumoto T; Iwatsuki M; Satake H; Kobayashi K; Esaki T; Nakashima Y; Kawanaka H; Emi Y; Komatsu Y; Shimokawa M; Makiyama A; Saeki H; Oki E; Baba H; Mori M
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):217-223. PubMed ID: 31768696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06).
    Kimura Y; Fujii M; Masuishi T; Nishikawa K; Kunisaki C; Matsusaka S; Segawa Y; Nakamura M; Sasaki K; Nagao N; Hatachi Y; Yuasa Y; Asami S; Takeuchi M; Furukawa H; Nakajima T;
    Gastric Cancer; 2018 May; 21(3):421-427. PubMed ID: 28936560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer.
    Kataoka H; Mori Y; Shimura T; Nishie H; Natsume M; Mochizuki H; Hirata Y; Sobue S; Mizushima T; Sano H; Mizuno Y; Nakamura M; Hirano A; Tsuchida K; Adachi K; Seno K; Kitagawa M; Kawai T; Joh T
    Cancer Chemother Pharmacol; 2016 May; 77(5):957-62. PubMed ID: 27002325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial.
    Rivera F; Romero C; Jimenez-Fonseca P; Izquierdo-Manuel M; Salud A; Martínez E; Jorge M; Arrazubi V; Méndez JC; García-Alfonso P; Reboredo M; Barriuso J; Muñoz-Unceta N; Jimeno R; López C
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1175-1181. PubMed ID: 30927036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II Prospective Study of Trastuzumab in Combination with S-1 and Oxaliplatin (SOX100) Therapy for HER2-Positive Advanced Gastric Cancer.
    Mori Y; Kataoka H; Ebi M; Adachi K; Yamaguchi Y; Hayashi N; Hirata Y; Sobue S; Ishihara R; Suzuki Y; Mizushima T; Inoue Y; Hasegawa I; Ono S; Hirano A; Kimura Y; Seno K; Ozeki K; Shimura T; Kubota E
    J Gastrointest Cancer; 2022 Dec; 53(4):930-938. PubMed ID: 34550548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial.
    Gong J; Liu T; Fan Q; Bai L; Bi F; Qin S; Wang J; Xu N; Cheng Y; Bai Y; Liu W; Wang L; Shen L
    BMC Cancer; 2016 Feb; 16():68. PubMed ID: 26857702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of S-1 plus oxaliplatin 130 mg/m
    Kashiwada T; Shinozaki K; Ueno S; Kawanaka H; Uno F; Okita Y; Fukahori M; Matsushita H; Emi Y; Shimokawa M; Makiyama A; Saeki H; Oki E; Maehara Y; Mori M; Baba E;
    Int J Clin Oncol; 2021 Feb; 26(2):345-354. PubMed ID: 33085058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer.
    Ryu MH; Yoo C; Kim JG; Ryoo BY; Park YS; Park SR; Han HS; Chung IJ; Song EK; Lee KH; Kang SY; Kang YK
    Eur J Cancer; 2015 Mar; 51(4):482-488. PubMed ID: 25661103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multi-institution phase II study of docetaxel and S-1 in combination with trastuzumab for HER2-positive advanced gastric cancer (DASH study).
    Kagawa S; Muraoka A; Kambara T; Nakayama H; Hamano R; Tanaka N; Noma K; Tanakaya K; Kishimoto H; Shigeyasu K; Kuroda S; Kikuchi S; Kuwada K; Nishizaki M; Shirakawa Y; Fujiwara T
    Cancer Chemother Pharmacol; 2018 Feb; 81(2):387-392. PubMed ID: 29290024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
    Kawazoe A; Yamaguchi K; Yasui H; Negoro Y; Azuma M; Amagai K; Hara H; Baba H; Tsuda M; Hosaka H; Kawakami H; Oshima T; Omuro Y; Machida N; Esaki T; Yoshida K; Nishina T; Komatsu Y; Han SR; Shiratori S; Shitara K
    Eur J Cancer; 2020 Apr; 129():97-106. PubMed ID: 32145474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1).
    Kurokawa Y; Sugimoto N; Miwa H; Tsuda M; Nishina S; Okuda H; Imamura H; Gamoh M; Sakai D; Shimokawa T; Komatsu Y; Doki Y; Tsujinaka T; Furukawa H
    Br J Cancer; 2014 Mar; 110(5):1163-8. PubMed ID: 24473399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study.
    Meulendijks D; Beerepoot LV; Boot H; de Groot JW; Los M; Boers JE; Vanhoutvin SA; Polee MB; Beeker A; Portielje JE; de Jong RS; Goey SH; Kuiper M; Sikorska K; Beijnen JH; Tesselaar ME; Schellens JH; Cats A
    Invest New Drugs; 2016 Feb; 34(1):119-28. PubMed ID: 26643663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploratory analysis of serum HER2 extracellular domain for HER2 positive gastric cancer treated with SOX plus trastuzumab.
    Wakatsuki T; Ishizuka N; Hironaka S; Minashi K; Kadowaki S; Goto M; Shoji H; Hirano H; Nakayama I; Osumi H; Ogura M; Chin K; Yamaguchi K; Takahari D
    Int J Clin Oncol; 2024 Jun; 29(6):801-812. PubMed ID: 38589679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab With S-1 Plus Cisplatin in HER2-positive Advanced Gastric Cancer Without Measurable Lesions: OGSG 1202.
    Endo S; Kurokawa Y; Gamoh M; Kimura Y; Matsuyama J; Taniguchi H; Takeno A; Kawabata R; Kawada J; Masuzawa T; Yamamoto K; Kobayashi K; Sakai D; Shimokawa T; Satoh T
    Anticancer Res; 2019 Feb; 39(2):1059-1065. PubMed ID: 30711995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study protocol of a phase II clinical trial (KSCC1501A) examining oxaliplatin + S-1 for treatment of HER2-negative advanced/recurrent gastric cancer previously untreated with chemotherapy.
    Saeki H; Emi Y; Oki E; Tokunaga S; Kakeji Y; Akagi Y; Baba H; Baba E; Maehara Y;
    BMC Cancer; 2018 Jan; 18(1):57. PubMed ID: 29310611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized Phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301 (Trigger Study).
    Kataoka K; Tokunaga M; Mizusawa J; Machida N; Katayama H; Shitara K; Tomita T; Nakamura K; Boku N; Sano T; Terashima M; Sasako M;
    Jpn J Clin Oncol; 2015 Nov; 45(11):1082-6. PubMed ID: 26355164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early tumor shrinkage and depth of response in patients with advanced gastric cancer: a retrospective analysis of a randomized phase III study of first-line S-1 plus oxaliplatin vs. S-1 plus cisplatin.
    Nishina T; Azuma M; Nishikawa K; Gotoh M; Bando H; Sugimoto N; Amagai K; Chin K; Niwa Y; Tsuji A; Imamura H; Tsuda M; Yasui H; Fujii H; Yamaguchi K; Yasui H; Hironaka S; Shimada K; Miwa H; Mitome T; Kageyama H; Hyodo I
    Gastric Cancer; 2019 Jan; 22(1):138-146. PubMed ID: 29948386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial).
    Lee KW; Chung IJ; Ryu MH; Park YI; Nam BH; Oh HS; Lee KH; Han HS; Seo BG; Jo JC; Lee HR; Kim JW; Park SR; Cho SH; Kang YK;
    Gastric Cancer; 2021 Jan; 24(1):156-167. PubMed ID: 32596783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer.
    Yamada Y; Higuchi K; Nishikawa K; Gotoh M; Fuse N; Sugimoto N; Nishina T; Amagai K; Chin K; Niwa Y; Tsuji A; Imamura H; Tsuda M; Yasui H; Fujii H; Yamaguchi K; Yasui H; Hironaka S; Shimada K; Miwa H; Hamada C; Hyodo I
    Ann Oncol; 2015 Jan; 26(1):141-148. PubMed ID: 25316259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.